Lupus
Immunology· 2 reviewed drugs· 1755 cited findings behind them
What the regulatory reviews cover
This page provides an overview of drugs for Lupus that have undergone regulatory review and are included in this library. Saphnelo is indicated as an add-on therapy for adult patients with moderate to severe, active autoantibody-positive systemic lupus erythematosus (SLE) despite standard therapy. For Saphnelo, the Anifrolumab average KD on human PBMCs was 0.29. Benlysta is indicated as an add-on therapy in adult patients with active autoantibody-positive systemic lupus erythematosus (SLE) with a high degree of disease activity despite standard therapy. For Benlysta, the SELENA SLEDAI >=4 point reduction from baseline at Week 52 was 35.6.
It is important to note that these drugs were studied in different trials, and therefore the figures presented are not directly comparable head-to-head. The information provided reflects the specific results reported in their respective regulatory review documents.
The drugs — one cited result each
| Saphnelo AstraZeneca PLC | Anifrolumab average KD on human PBMCs: 0.29 AstraZeneca PLC — Saphnelo EMA EPAR public assessment report, p.26 |
| Benlysta GSK plc | SELENA SLEDAI >=4 point reduction from baseline at Week 52: 35.6 GSK plc — Benlysta EMA EPAR public assessment report (EMEA/H, p.44 |
Different drugs were studied in different trials — these figures are not head-to-head comparisons.
Explore the full evidence
Every finding behind these drugs — searchable, comparable and answerable in plain language — is in the Immunology research library →
Lists reflect the regulatory review documents in this library, not all therapies that exist. Educational reference only — not medical or investment advice.